ARGX
Price
$590.06
Change
+$6.44 (+1.10%)
Updated
Apr 3 closing price
Capitalization
35.87B
34 days until earnings call
PMN
Price
$0.64
Change
-$0.07 (-9.86%)
Updated
Apr 3 closing price
Capitalization
20.92M
46 days until earnings call
Ad is loading...

ARGX vs PMN

Header iconARGX vs PMN Comparison
Open Charts ARGX vs PMNBanner chart's image
argenx SE
Price$590.06
Change+$6.44 (+1.10%)
Volume$659.94K
Capitalization35.87B
ProMIS Neurosciences
Price$0.64
Change-$0.07 (-9.86%)
Volume$35.2K
Capitalization20.92M
ARGX vs PMN Comparison Chart
Loading...
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGX vs. PMN commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a StrongBuy and PMN is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ARGX: $590.06 vs. PMN: $0.64)
Brand notoriety: ARGX and PMN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 214% vs. PMN: 91%
Market capitalization -- ARGX: $35.87B vs. PMN: $20.92M
ARGX [@Biotechnology] is valued at $35.87B. PMN’s [@Biotechnology] market capitalization is $20.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whilePMN’s FA Score has 0 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • PMN’s FA Score: 0 green, 5 red.
According to our system of comparison, ARGX is a better buy in the long-term than PMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 4 TA indicator(s) are bullish while PMN’s TA Score has 6 bullish TA indicator(s).

  • ARGX’s TA Score: 4 bullish, 4 bearish.
  • PMN’s TA Score: 6 bullish, 1 bearish.
According to our system of comparison, PMN is a better buy in the short-term than ARGX.

Price Growth

ARGX (@Biotechnology) experienced а -0.57% price change this week, while PMN (@Biotechnology) price change was -8.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

ARGX is expected to report earnings on May 08, 2025.

PMN is expected to report earnings on May 20, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGX($35.9B) has a higher market cap than PMN($20.9M). ARGX has higher P/E ratio than PMN: ARGX (45.67) vs PMN (6.46). ARGX YTD gains are higher at: -4.055 vs. PMN (-32.465). PMN has higher annual earnings (EBITDA): -391.76K vs. ARGX (-60.47M). ARGX has more cash in the bank: 3.1B vs. PMN (21.6M). PMN has less debt than ARGX: PMN (4.05M) vs ARGX (34M). ARGX has higher revenues than PMN: ARGX (1.86B) vs PMN (0).
ARGXPMNARGX / PMN
Capitalization35.9B20.9M171,770%
EBITDA-60.47M-391.76K15,435%
Gain YTD-4.055-32.46512%
P/E Ratio45.676.46707%
Revenue1.86B0-
Total Cash3.1B21.6M14,361%
Total Debt34M4.05M840%
FUNDAMENTALS RATINGS
ARGX vs PMN: Fundamental Ratings
ARGX
PMN
OUTLOOK RATING
1..100
145
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
12100
SMR RATING
1..100
9292
PRICE GROWTH RATING
1..100
4965
P/E GROWTH RATING
1..100
5298
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARGX's Valuation (78) in the Pharmaceuticals Other industry is in the same range as PMN (95) in the null industry. This means that ARGX’s stock grew similarly to PMN’s over the last 12 months.

ARGX's Profit vs Risk Rating (12) in the Pharmaceuticals Other industry is significantly better than the same rating for PMN (100) in the null industry. This means that ARGX’s stock grew significantly faster than PMN’s over the last 12 months.

ARGX's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as PMN (92) in the null industry. This means that ARGX’s stock grew similarly to PMN’s over the last 12 months.

ARGX's Price Growth Rating (49) in the Pharmaceuticals Other industry is in the same range as PMN (65) in the null industry. This means that ARGX’s stock grew similarly to PMN’s over the last 12 months.

ARGX's P/E Growth Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for PMN (98) in the null industry. This means that ARGX’s stock grew somewhat faster than PMN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXPMN
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
54%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
60%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
67%
N/A
View a ticker or compare two or three
Ad is loading...
ARGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RLX1.84-0.03
-1.60%
RLX Technology
AVXL8.30-0.26
-3.04%
Anavex Life Sciences Corp
NWSA26.07-0.99
-3.66%
News Corp
ISPR2.69-0.11
-3.93%
Ispire Technology
CMLS0.44-0.05
-10.13%
Cumulus Media

ARGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ARGNF. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ARGNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGX
1D Price
Change %
ARGX100%
+1.10%
ARGNF - ARGX
55%
Loosely correlated
N/A
BBIO - ARGX
46%
Loosely correlated
-1.59%
IONS - ARGX
42%
Loosely correlated
-0.66%
ALNY - ARGX
40%
Loosely correlated
-1.75%
AXON - ARGX
40%
Loosely correlated
-3.35%
More

PMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PMN has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMN
1D Price
Change %
PMN100%
-9.96%
SYRE - PMN
44%
Loosely correlated
-9.68%
BBIO - PMN
42%
Loosely correlated
-1.59%
ABOS - PMN
33%
Poorly correlated
-8.52%
LIXT - PMN
27%
Poorly correlated
-2.87%
ARGX - PMN
25%
Poorly correlated
+1.10%
More